Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: D. K. G. who wrote (32016)	3/18/2005 11:14:51 AM
From: D. K. G.	Respond to of 120411

AGNT.OB (.84) 21.2 million buyout with shares out 20.69 million represents 1.02 per share a 21% preamium. Biotage Acquires All Of Argonaut Technologies Business DOW JONES NEWSWIRES March 18, 2005 5:50 a.m. Edited Press Release STOCKHOLM -- Swedish life science research company Biotage AB (BIOT-A.SK) Friday said it will acquire all of U.S. Argonaut Technologies Inc.'s (AGNT) business instead of only the reagents business, as was announced earlier. The total acquisition price thus becomes SEK145 million which is paid in cash, the company said. Beside the reagents business Argonaut also has a process instrument business. Biotage estimates it will increase its sales by around SEK125 million a year through the acquisition. "We estimate that the acquisition will have a positive effect on our results already this year," Biotage's Chief Executive, Jeff Bork, said. Last year Argonaut reported reagents sales of about SEK100 million and the process instrument sales was about SEK40 million, of which SEK25 million emanated from products which Biotage intends to continue. Biotage said it has received a short-term bank loan to finance the acquisition but is evaluating different financing solutions and will present a long-term solution in short. If a new share issue is carried out, the present main shareholders HealthCap AB, Investor Growth Capital, owned by Investor AB (INVE-B.SK) and Catella Healthcare, part of Generics Group AG (GEN.LN), have committed to guarantee the new share issue amounting to the sales price in full, Biotage said. The company said the acquisition is dependent on the final approval of a general meeting of the shareholders in Argonaut Technologies Inc.